Conversion from cyclosporin to azathioprine after kidney transplantation

[1]  M. Seed,et al.  Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  F. Kronenberg,et al.  Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[3]  G. Opelz,et al.  Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome. , 1994, Transplantation.

[4]  J. H. van Bockel,et al.  LONG‐TERM CARDIOVASCULAR MORBIDITY AND MORTALITY IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE PATIENTS AFTER RENAL TRANSPLANTATION , 1994, Transplantation.

[5]  F. Kronenberg,et al.  Thromboembolic complications in renal allograft recipients: triple-drug therapy in comparison with cyclosporine A-prednisone , 1993 .

[6]  R. Heyka,et al.  Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Hemodialysis Patients , 1992, Circulation.

[7]  A. Sheil,et al.  Comparison of three immunosuppressive regimens in cadaver renal transplantation: long-term cyclosporine, short-term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. , 1988, The New England journal of medicine.

[8]  J. Wetzels,et al.  CYCLOSPORIN TREATMENT WITH CONVERSION AFTER THREE MONTHS VERSUS CONVENTIONAL IMMUNOSUPPRESSION IN RENAL ALLOGRAFT RECIPIENTS , 1987, The Lancet.

[9]  T. Strom,et al.  CONVERSION FROM CYCLOSPORINE TO AZATHIOPRINE IN RENAL ALLOGRAFT RECIPIENTS , 1984, Transplantation.